Related Experiment Video
Updated: Dec 30, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Precision Management of Advanced Non-Small Cell Lung Cancer
Ching-Yao Yang1, James Chih-Hsin Yang2, Pan-Chyr Yang1,3
1Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan;
Abstract:
The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non-small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non-small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future.
Insights
Advanced lung cancer treatment has shifted to precision medicine, significantly improving survival through targeted therapies and immunotherapies for non-small cell lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Lung cancer treatment has evolved from traditional chemotherapy to targeted therapies.
- Recent advances include small molecules for tyrosine kinase receptors and immune checkpoint inhibitors.
- These innovations have improved survival rates for advanced and metastatic non-small cell lung cancer.
Purpose of the Study:
- To review the evolution of advanced lung cancer treatment.
- To highlight the impact of precision medicine, including targeted therapies and immunotherapies.
- To discuss future directions in lung cancer management.
Main Methods:
- Review of scientific literature on advanced lung cancer treatment.
- Analysis of the development and impact of targeted therapies (e.g., tyrosine kinase inhibitors).
- Evaluation of the role and advancements in immune checkpoint inhibitors and immunotherapy.
Main Results:
- Significant improvements in survival for metastatic non-small cell lung cancer patients.
- Current guidelines emphasize identifying targetable mutations and immune checkpoints.
- Personalized medicine approaches are now central to treatment strategies.
Conclusions:
- Precision medicine, targeting specific mutations and immune checkpoints, has transformed non-small cell lung cancer care.
- Future research should focus on novel genetic targets, immunotherapy biomarkers, and combination therapies.
- Continued investigation is crucial for further enhancing treatment outcomes in lung cancer.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
